Table 1.
Potential drugs target to cPLA2 in central nervous system trauma
| Drug | Target | Disease | Therapeutic effects | References |
|---|---|---|---|---|
| AACOCF3 | cPLA2 | Spinal cord injury | Reducing membrane injury and inflammation, decreasing tissue damage, and improving behavioral recovery | Liu et al., 2014 |
| cPLA2 | CCI induced TBI | Restoring autophagic flow, weakening cortical cellular deaths, and ameliorating movement and cognition functions | Chinmoy et al., 2019 | |
| PACOCF3 | cPLA2 and Ca2+ | Spinal cord injury | Blocking myelin’s detrimental effects of increasing proinflammatory cell factors, reactive oxygen species, and nitric oxide generation in M1 macrophages | Kopper et al., 2021 |
| ANXA1 | Membrane phospholipids | Spinal cord injury | Improving tissue repair, reconstruction, regeneration, increasing white matter sparing, and protecting axons of long descending pathways | Liu et al., 2007 |
| U0126 | ERK1/2 | DCS spinal injury | Attenuating oxidative stress and inflammatory response, and improving motor function by upregulating heat shock protein 32 | Quan et al., 2021 |
| SB203580 | MAPK AP kinase-2&3 | Spinal cord injury | Preventing the delayed progressive degeneration of oligodendrocytes and promoting recovery of motor function | Hideki et al., 2003 |
| Celecoxib | LOX/COX-2 | Spinal cord injury | Attenuating oxidative stress, apoptosis, and inflammation | An et al., 2020 |
| Salsalate | LOX/COX-2 | CCI induced TBI | Blocking pro-inflammatory gene expression and nitrite secretion by microglia | Lagraoui et al., 2017 |
CCI: Controlled cortical impact; COX-2: cyclooxygenase-2; cPLA2: cytosolic phospholipase A2; DCS: decompression sickness; ERK: extracellular signal regulated kinase; LOX: lipoxygenase; TBI: traumatic brain injury.